Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
AMRN 
Amarin Corporation PLC (AMRN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/20/2025: AMRN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $10.5
1 Year Target Price $10.5
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 2 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 26.52% | Avg. Invested days 41 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 06/20/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 325.31M USD | Price to earnings Ratio - | 1Y Target Price 10.5 |
Price to earnings Ratio - | 1Y Target Price 10.5 | ||
Volume (30-day avg) 3 | Beta 0.72 | 52 Weeks Range 7.08 - 17.18 | Updated Date 06/30/2025 |
52 Weeks Range 7.08 - 17.18 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.4 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -41.07% | Operating Margin (TTM) -39.88% |
Management Effectiveness
Return on Assets (TTM) -5.06% | Return on Equity (TTM) -17.25% |
Valuation
Trailing PE - | Forward PE 500 | Enterprise Value 51253086 | Price to Sales(TTM) 1.52 |
Enterprise Value 51253086 | Price to Sales(TTM) 1.52 | ||
Enterprise Value to Revenue 0.24 | Enterprise Value to EBITDA -5.8 | Shares Outstanding 20707000 | Shares Floating 375124088 |
Shares Outstanding 20707000 | Shares Floating 375124088 | ||
Percent Insiders 1.7 | Percent Institutions 18.21 |
Analyst Ratings
Rating 2 | Target Price 10.5 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 1 | Sell 2 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Amarin Corporation PLC
Company Overview
History and Background
Amarin Corporation PLC was founded in 1989. Initially focused on CNS disorders, it transitioned to cardiovascular disease with Vascepa. Significant milestones include FDA approval of Vascepa and subsequent label expansions.
Core Business Areas
- Pharmaceutical Development and Commercialization: Focuses on the development and commercialization of therapeutics for cardiovascular disease and other related indications.
- Vascepa: Commercialization of Vascepa (icosapent ethyl) capsules, a prescription-only omega-3 fatty acid derivative.
Leadership and Structure
The leadership team consists of Patrick Holt (President and CEO), Tom Reilly (Chief Financial Officer), and other key executives. The organizational structure is typical of a pharmaceutical company, with departments for R&D, commercial operations, manufacturing, and finance.
Top Products and Market Share
Key Offerings
- Vascepa (icosapent ethyl): Vascepa is a prescription-only omega-3 fatty acid derivative indicated to reduce the risk of cardiovascular events among adults with elevated triglyceride levels and either established cardiovascular disease or diabetes and other risk factors. Vascepa generated significant revenue for Amarin before generic entry. Market share has decreased due to generic competition. Key competitors include generic manufacturers and other omega-3 products like Lovaza (GSK - now Viatris) and dietary supplements.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated. The market for cardiovascular disease treatments is substantial and growing, driven by an aging population and increasing prevalence of risk factors.
Positioning
Amarin was a key player in the prescription omega-3 space with Vascepa, but its competitive advantage has been eroded by generic entry. It needs to innovate to regain its footing.
Total Addressable Market (TAM)
The cardiovascular disease therapeutics market is estimated to be worth hundreds of billions of dollars annually. Vascepa targeted a significant sub-segment within this, but its competitive position has changed.
Upturn SWOT Analysis
Strengths
- Prior FDA approval and clinical data for Vascepa
- Established commercial infrastructure
- Strong patent protection (prior to generic entry)
Weaknesses
- Loss of exclusivity for Vascepa
- Dependence on a single product (Vascepa)
- High marketing expenses
Opportunities
- Develop new formulations or indications for icosapent ethyl
- Expand into new markets
- Acquire or license new assets
Threats
- Generic competition for Vascepa
- Pricing pressures from payers
- Regulatory changes
Competitors and Market Share
Key Competitors
- GILD
- VTRS
- HLN
- CRBP
Competitive Landscape
Amarin now faces significant competition from generic manufacturers of icosapent ethyl. Other competitors include companies with alternative cardiovascular therapies.
Growth Trajectory and Initiatives
Historical Growth: Amarin experienced significant revenue growth with Vascepa prior to generic entry.
Future Projections: Future growth is uncertain and dependent on Amarin's ability to develop new products or expand into new markets.
Recent Initiatives: Amarin is likely focused on cost-cutting measures and exploring new strategic options.
Summary
Amarin faces significant challenges due to generic competition for Vascepa, impacting its revenue and profitability. The company needs to innovate to regain its market position. Its future depends on developing new products or expanding into new markets. Cost-cutting and strategic options are crucial to its survival.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Amarin Corporation PLC
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 1993-04-01 | CEO, President & Director Mr. Aaron D. Berg | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 275 | Website https://www.amarincorp.com |
Full time employees 275 | Website https://www.amarincorp.com | ||
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally through wholesalers, selected regional wholesalers, and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin 2, Ireland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.